Characterizing On‐Chip Angiogenesis Induction in a Microphysiological System as a Functional Measure of Mesenchymal Stromal Cell Bioactivity
Advanced Biology · 2024
DOI: 10.1002/adbi.202300094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Biology, 2024. Verfasst von Johnny Lam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Office of Therapeutic Product, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Sp…. Hauptthemen laut MEDLINE: Angiogenesis, Coculture Techniques, Mesenchymal Stem Cells, Microphysiological Systems. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Office of Therapeutic Product, US Department of Education and US FDA, National Research Foundation of Korea.
Abstract (Originalsprache)
Mesenchymal stromal cells (MSCs) continue to be proposed for clinical investigation to treat myriad diseases given their purported potential to stimulate endogenous regenerative processes, such as angiogenesis. However, MSC functional heterogeneity has hindered clinical success and still poses a substantial manufacturing challenge from a product quality control perspective. Here, a quantitative bioassay based on an enhanced‐throughput is described, microphysiological system (MPS) to measure the specific bioactivity of MSCs to stimulate angiogenesis as a potential measure of MSC potency. Using this novel bioassay, MSCs derived from multiple donors at different passages are co‐cultured with human umbilical vein endothelial cells and exhibit significant heterogeneity in angiogenic potency between donors and cell passage. Depending on donor source and cellular passage number, MSCs varied in their ability to stimulate tip cell dominant or stalk cell dominant phenotypes in angiogenic sprout morphology which correlated with expression levels of hepatocyte growth factor (HGF). These findings suggest that MSC angiogenic bioactivity may be considered as a possible potency attribute in MSC quality control strategies. Development of a reliable and functionally relevant potency assay for measuring clinically relevant potency attributes of MSCs will help to improve consistency in quality and thereby, accelerate clinical development of these cell‐based products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Office of Therapeutic Product, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
- Department of Mechanical Engineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
- Qureator, Inc., 7094 Miratech Drive, Suite 110, San Diego, CA, 92121, USA.
- Institute of Advanced Machines and Design, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
ORCID-Profile: Kyung E Sung
Förderung
- Office of Therapeutic Product
- US Department of Education and US FDA
- National Research Foundation of Korea
Zitieren
APA
Lam, J., Yu, J., Lee, B., Campagna, C., Yoo, S., Baek, K., Jeon, N. L., & Sung, K. E. (2024). Characterizing On‐Chip Angiogenesis Induction in a Microphysiological System as a Functional Measure of Mesenchymal Stromal Cell Bioactivity. Advanced Biology. https://doi.org/10.1002/adbi.202300094
Vancouver
Lam J, Yu J, Lee B, Campagna C, Yoo S, Baek K, et al. Characterizing On‐Chip Angiogenesis Induction in a Microphysiological System as a Functional Measure of Mesenchymal Stromal Cell Bioactivity. Advanced Biology. 2024. doi:10.1002/adbi.202300094
BibTeX
@article{Lam2024,
author = {Lam, Johnny and Yu, James and Lee, Byungjun and Campagna, Courtney and Yoo, Sanghee and Baek, Kyusuk and Jeon, Noo Li and Sung, Kyung E},
title = {Characterizing On‐Chip Angiogenesis Induction in a Microphysiological System as a Functional Measure of Mesenchymal Stromal Cell Bioactivity},
journal = {Advanced Biology},
year = {2024},
doi = {10.1002/adbi.202300094}
}
EUVIMED